Outlook Therapeutics, Inc.
OTLK · NASDAQ · USD
$0.5989
+0.0349 6.19%todayNot financial advice.
- Open
- 0.5675
- Day range
- 0.5557 - 0.6050
- 52-week range
- 0.1611 - 2.54
- Volume
- 3.69M
- Market cap
- 145.8M
- P/E ratio
- —
- EPS
- —
- Dividend yield
- 0.00%
- Beta
- 2.89
Performance
W
+1.51%
1M
−6.38%
3M
−64.14%
6M
+160.39%
YTD
−6.54%
Y
−53.21%
5Y
−98.69%
All
−99.90%
In the news
Oct 9
Outlook Therapeutics Appoints Greg DiPasquale as Chief Commercial Officer
Outlook Therapeutics named Greg DiPasquale as CCO to lead the upcoming U.S. commercial launch of its FDA-approved wet AMD treatment, LYTENAVA.
Company news
Oct 9
Outlook Therapeutics Appoints Greg DiPasquale as Chief Commercial Officer Ahead of US Drug Launch
Outlook Therapeutics has named Greg DiPasquale as Chief Commercial Officer as it prepares to launch its eye disease treatment in the U.S.
Company news
Embed on your site
Embed docsAdd a live price card or a chart to any page. Free, no sign-up; cards refresh every minute and link back here.
<iframe src="https://stocks.freetheai.org/embed/NASDAQ-OTLK" width="340" height="170" style="border:0;max-width:100%" loading="lazy" title="Outlook Therapeutics, Inc. (OTLK) - FreeTheAI Stocks"></iframe>
<p style="font-size:12px"><a href="https://stocks.freetheai.org/symbols/NASDAQ-OTLK">OTLK stock price</a> by FreeTheAI Stocks</p>